Background. Bupivacaine has a lower incidence of transient neurological symptoms than lidocaine after intrathecal (i.t.) injection. The increased toxic potential of lidocaine does not support its use in the clinical setting and could be related to augmented levels of spinal prostaglandin E 2 (PGE 2 ). We tested whether levobupivacaine leads to lower PGE 2 levels than lidocaine. Moreover, we compared the release of PGE 2 and glutamate after i.t. injections of levobupivacaine or lidocaine.
In humans, intrathecal (i.t.) lidocaine administration has been reported with a seven-fold increased incidence of transient neurological symptoms (TNS) when compared with bupivacaine (7.4 per 10 000 vs 1 per 10 000). 1 Furthermore, lidocaine has the potential to cause more neurotoxicity than other local anaesthetics when given at higher i.t. concentrations and doses than those used clinically. 2 -6 The mechanisms underlying this reduced margin of safety are still obscure. 7 Recently, we demonstrated in a rat microdialysis spinal cord study that i.t. lidocaine administration was accompanied by transiently increased prostaglandin E 2 (PGE 2 ) levels in cerebrospinal fluid (CSF) and mechanical hyperalgesia, suggesting a shortlasting period of spinal sensitization. 8 Whether other local anaesthetics with a reduced incidence for TNS after i.t. administration would have less influence on increases of PGE 2 levels still needs to be further explored. In this setting, we tested levobupivacaine, the preservative-free L-enantiomer of the racemate bupivacaine. Levobupivacaine is considered to be a safer analogue than racemic bupivacaine with reduced cardiovascular 9 and neurological sideeffects. 10 -12 Except for an i.t. rat cauda equina model in which similar histopathological neurotoxicity between bupivacaine and its enantiomers was shown, 13 literature on the spinal cord effects of levobupivacaine after i.t. administration is scarce. 14 TNS incidence does not change with dilution of the local anaesthetic dose. 15 16 Neither does it change when comparing i.t. 60 and 75 mg doses. 17 This contrasts with the incidence of more neurotoxic lidocaine effects, such as the cauda equina syndrome (CES) that tends to be associated with higher i.t. lidocaine doses. A different identity was suggested for the two clinical manifestations. Some reject a different identity and believe that TNS is at the lower end of a spectrum of lidocaine toxicity scale, whereas the more neurotoxic events of lidocaine are at its higher end. 18 We measured dialysate level changes in CSF of glutamate and PGE 2 as changes in these may be considered as surrogates for assessing local-anaesthetic-induced nociception or central hypersensitivity. 4 8 To further examine whether a relationship exists between potential transient PGE 2 changes and levobupivacaine dose, we investigated two doses corresponding to a normal and a large clinical i.t. injection and measured glutamate and concentrations in CSF.
We hypothesized that i.t. levobupivacaine injection will be accompanied by lower PGE 2 levels in CSF than levels observed after i.t. lidocaine injection. 8 We also investigated the exact time relationship between PGE 2 and glutamate changes in CSF. We compared residual PGE 2 and glutamate effects after two identical separated i.t. injections of either levobupivacaine or lidocaine, the second injection being given after full motor and sensory block recovery and 4 h after the first dose. The aim of the second i.t. injection was to evaluate the effect of a higher cumulative dose of levobupivacaine or lidocaine on spinal PGE 2 and glutamate changes without compromising the physical integrity of the animal after a single administration of an excessive dose.
Methods
The Bioethical Committee of animal experimentation of the Vrije Universiteit Brussel approved the experimental protocol, which complied with the guidelines for animal experimentation of the International Association for the Study of Pain and with the guidelines of the Belgian Ministry of Agriculture.
Implantation of the i.t. triple lumen loop catheter
Male Wistar rats of +300 g (B&K Universal Limited, UK) were anaesthetized using i.p. sodium pentobarbital (60 mg kg 21 ) for implantation of an i.t. triple lumen catheter with a single loop and three outlets (Marsil Scientific, San Diego, CA, USA). This allowed i.t. injection and dialysate sampling of CSF. The catheter was introduced via the atlanto-occipital membrane as described previously. 19 Briefly, the loop of the catheter was placed at the rostral margin of the lumbar enlargement and its free ends were externalized through the skin at the top of the skull. Surgery ended with a 50 ml s.c. injection of buprenorphine (Temgesic w 0.3 mg ml
21
, Schering-Plough, Brussels, Belgium) for postoperative analgesia.
Microdialysis experiment
After surgery, the rats were allowed to recover for 5 days. Rats showing neurological impediments were not used and were killed appropriately.
The rats were placed in a microdialysis cage (Freely Moving System BAS/Microdialysis, West Lafayette, IN, USA) in the microdialysis room the evening before the experiment to allow them to adjust to their new surroundings. On the day of the experiment, the dialysis probes were connected to a microdialysis pump (CMA 100, CMA/Microdialysis, Stockholm, Sweden) and perfused with a modified Ringer's solution (NaCl 147 mM, KCl 4 mM, and CaCl 2 2.3 mM) at a flow rate of 7.5 ml min 21 for at least 60 min.
Intrathecal injections
Levobupivacaine setting Baseline measurements (three samples of 10 min for PGE 2 and five samples of 10 min for glutamate) were followed by i.t. injection of either 20 ml ('Levo 100 mg') or 50 ml of levobupivacaine ('Levo 250 mg') (Chirocaine w , Abbott, Solbaevegen, Norway). A third, control group, received 50 ml i.t. saline ('Saline'). Dialysates of CSF were sampled at 10 min intervals for the first hour after injection and at 30 min intervals for another 3 h.
Repeated injection setting
Two groups of rats received lidocaine where 20 ml ('lido 400 mg') or 50 ml ('lido' 1000 mg) was injected i.t. (Linisol w 2% pro-injection, B. Braun, Melsungen, Germany). These experiments were performed as described previously. 8 The identical second i.t. dose was given after checking for total motor and sensory recovery of the rat, 4 h after the first dose. All solutions were injected manually by bolus injection at a rate of 10 ml per 40 s. Dialysates of CSF were sampled at 10 min intervals for the first hour after injection and at 30 min intervals for another 3 h. Additionally dialysates of CSF were sampled at 10 min intervals for another hour after the second injection. All samples were collected on ice and stored at -708C for subsequent analysis. We calculated the 20 min glutamate and 60 min PGE 2 area under the curve. Differences in 60 min PGE 2 and 20 min glutamate release after a first i.t. injection and the second injection were analysed.
Effects of i.t. administration of levobupivacaine and lidocaine
The decision to compare 60 min PGE 2 levels and 20 min glutamate levels was based on the magnitude and duration of glutamate and PGE 2 changes observed in previous studies. 4 8 Assay of PGE 2 
and glutamate in CSF
The concentration of PGE 2 in the microdialysate samples was quantified using a commercially available Correlate-EIA PGE 2 (competitive immunoassay) kit in accordance with the manufacturer's protocol (Assay Design, Inc., USA). The concentration of PGE 2 in the microdialysate samples was calculated from the measured optical density by means of four-parameter logistic regression. A standard curve was constructed between 39.4 and 5000 pg ml 21 . The concentrations of glutamate were analysed by narrow-bore liquid chromatography with fluorescence detection after pre-column derivation with ortho-phthalaldehyde and beta-mercaptoethanol, as described elsewhere. 20 The intra-and inter-assay coefficients of variation were 5.2% and 6.4% for PGE 2 , and 2.1% and 6.4% for glutamate, respectively.
Verification of probe positioning
The animals were killed after each experiment with an overdose of pentothal. That part of the spinal cord containing the i.t. catheter membrane was dissected. The position of the catheter in the spinal cord was confirmed by injecting methylene blue.
Data analysis
To evaluate the effects of the i.t. drug injections, we averaged the PGE 2 and glutamate baseline responses and set this average to 100%. Drug effects were expressed as %-change of baseline values. The glutamate and PGE 2 data are presented as %-change (SD). Statistical significance of differences was accepted at P,0.05. Data were analysed with Statistica System Reference 2001 (Statsoft Inc.
w ; Tulsa, OH, USA). Within group differences of PGE 2 and glutamate, data were analysed using the Wilcoxon test. Between-group global differences of PGE 2 and glutamate were analysed using one-way ANOVA. Least significant difference test was used for post hoc comparisons. The Mann -Whitney test was performed to detect between-group differences at fixed time intervals and to detect differences in AUC of the PGE 2 after i.t. injection.
Results
Forty rats without neurological sequelae from spinal microdialysis catheter insertion were studied (n¼8 per group). 21 for, respectively, the saline, the levo 100 and 250 mg, and the lido 400 and 1000 mg groups (n¼24 for each group).
Baseline levels
Baseline glutamate levels [mean (SD)] were: 0.34 (0.02), 0.35 (0.03), 0.37 (0.02), 0.34 (0.02), and 0.37 (0.02) mM, and for, respectively, the saline, the levo 100 and 250 mg, and the lido 400 and 1000 mg groups (n¼40 for each group).
Taking into account the individual range variability observed in baseline values for PGE 2 
Levobupivacaine-induced changes in PGE 2 and glutamate
In both the levo 100 and the 250 mg groups, spinal PGE 2 levels increased reaching peak values of, respectively, 410% and 500% of their baseline value after 40 and 30 min. A gradual return to normal baseline was seen after 90 min in both groups (Fig. 1A) .
After i.t. injection of levobupivacaine 100 or 250 mg, glutamate levels increased by 170% and 10% (Fig. 1B) within 10 min after i.t. administration. The glutamate concentrations rapidly returned to baseline within 20 min after levobupivacaine administration (Fig. 1B) .
Repeated injection setting
We observed in the lido 1000 mg group, an increased (P¼0.035) PGE 2 release in CSF after the second injection (ratio: 1.70). In the lido 400 mg group, a tendency (P¼0.20) (Lido 400 mg) of increased PGE 2 release after the second injection was observed (ratio: 1.65). In contrast, the 60 min PGE 2 values steadied in the levobupivacaine groups after the second injection (ratio ,1) (Fig. 2A) .
Glutamate release in CSF was equal in all treatment groups. A second injection of lidocaine or levobupivacaine did not influence glutamate release. Comparable glutamate values were found after the second injection of levobupivacaine (100 or 250 mg) and lidocaine (1000 or 400 mg) (Fig. 2B ).
Discussion Surprisingly, this investigation shows that two different doses of i.t. administered levobupivacaine are accompanied by 50 -90 min PGE 2 increases in CSF. These PGE 2 increases happen simultaneously with glutamate within the first 10 min. Our microdialysis setting where dialysates were collected at fixed time intervals did not allow us, however, to determine the exact timing of release. The observed glutamate releases with levobupivacaine in CSF are not different in time or magnitude from those previously reported with bupivacaine in rabbits. 4 Compared with our previous investigation with i.t. lidocaine, 8 we observed different durations of PGE 2 increases after i.t. levobupivacaine when compared with baseline levels: 120 min in the lido 1000 mg group vs 50 min for the lido 400 mg group and 90 min for both the levo groups. We also observed a different time to peak of PGE 2 levels with a slight rightward shift of PGE 2 increase after i.t. levobupivacaine. We believe that these differences are related to the different PD and PK profiles and onsets, peaks of action, and duration times of lidocaine and levobupivacaine.
The physiological background behind our model can be explained as following: i.t. lidocaine or levobupivacaine induces dorsal horn neuronal circuitry activation in which PGE 2 is involved. Glutamate is released by i.t. lidocaine or levobupivacaine injection and induces a post-synaptic depolarization. The post-synaptic depolarization then leads indirectly to an increase of intracellular calcium, which in turn results in activation of a number of intracellular enzymes, including phospholipase A 2 (PLA 2 ). PLA 2 activation then induces an increase in cytosolic arachidonic acid, which will enter the cyclooxygenase cascade leading to the synthesis of a variety of prostaglandins that gain access to the extracellular space. Prostanoids then affect presynaptic prostanoid E receptors that further increase intracellular calcium in sensory afferents and depolarize dorsal horn neurones and increase spinal excitability. 21 The second i.t. injection given after full motor and sensory block recovery made it possible to evaluate the effects of higher cumulative doses of lidocaine and levobupivacaine and to observe possible residual PGE 2 effects after a first i.t. dose. Using this approach, we found that the 60 min AUC of PGE 2 values were higher after Effects of i.t. administration of levobupivacaine and lidocaine a second 1000 mg dose of lidocaine than after a second dose of 400 mg lidocaine or after both levobupivacaine administrations. This interesting finding may point to a more important anaesthetic dose-related cumulative PGE 2 effect after a double injection of 1000 mg of lidocaine than after lidocaine 400 mg or levobupivacaine 250 or 100 mg. As high PGE 2 levels in CSF 21 22 have repeatedly been linked with persisting central pain sensitization and abnormal pain hypersensitivity, we believe that this finding may corroborate the higher incidence of reported TNS with lidocaine. The high PGE 2 lidocaine levels found are in agreement with previously demonstrated levels, which were accompanied with transient mechanical hyperalgesia and increased heat sensitization.
It has been hypothesized that TNS reflects transient local anaesthetic neurotoxicity, which is reversible at low dose and interacts with multiple incompletely characterized factors that modulate pain perception. 18 Interestingly, our observed PGE 2 changes may, as suggested before, 8 run parallel with this hypothesis. Similarly, the transient PGE 2 changes after i.t. lidocaine or levobupivacaine may mirror the transiently increased calcium changes in cytoplasmatic (lidocaine) or endoplasmatic (bupivacaine) reticulum observed after local anaesthetic administration in cell line cultures. 23 24 In line with these in vitro investigations, where lidocaine in the higher dose range gave more marked calcium increases than for other local anaesthetics, we found that in our investigation, increasing lidocaine dose by a second injection was accompanied by higher PGE 2 increases. This was in contrast with levobupivacaine, where no dose-related PGE 2 increases were found after a second injection.
There might be some evidence for CES in this setting as the inserted spinal microdialysis catheter may be coiled near the insertion site or be directed caudally with the tip of the catheter in the dural sac. In addition, injecting through an i.t. catheter may result in an increased incidence of localized drug misdistribution in the dural sac with subsequent increased incidence of CES. However, we killed all our rats at the end of surgery and checked the position of the probe by meticulous dissection after injection of methylene blue. The rats also did not receive a high-dose continuous infusion of local anaesthetics through the catheter, 13 but two single i.t. injections. We therefore think it is highly unlikely that the observed PGE 2 changes were related to CES, but rather believe that the observed PGE 2 changes after i.t. levobupivacaine and lidocaine may reflect initiating reversible white matter damage 25 and a subsequent self-limiting inflammation induced. The resulting effect after i.t. injection might also be dependent on previous nervous inflammation, on existing vasa nervosum atherosclerosis, and on the extent of rostral spread and distribution of the anaesthetic after i.t. injection. Further studies are therefore needed to establish the relationship between morphological changes induced in vitro and the occurrence of clinical symptoms of TNS or CES and PGE 2 changes.
Whether the syndrome of TNS is to be considered as a manifestation of mild, transient lidocaine neurotoxicity is still controversial, because TNS does not seem to be as closely associated with either a high dose or sacral pooling of lidocaine. 26 We did not compare exact equipotent i.t. doses. Taking into account the 1:4.70 (95% CI 3.65 -7.07) lidocaine/ bupivacaine potency ratio for i.t. injection in rats 6 and the suggested equipotent potency ratios between bupivacaine and levobupivacaine, 27 we should have given 470 and 1175 mg of lidocaine to achieve equipotent doses. Nevertheless, we believe that the i.t. administration of exact equipotent doses of lidocaine would probably not alter our conclusions. Similarly, we believe as found by others that decreasing the concentration by dilution or increasing the concentration but keeping the same dose is unlikely to change our results. 15 16 There are practical implications of this rat laboratory investigation for the clinical arena, though confirmation in humans is needed. Our results suggest a lidocaine dose-related incidence of PGE 2 increase and possibly TNS. Furthermore, though the clinical safety margin after single administration of i.t. bupivacaine or its analogues is reported to be improved in comparison with i.t. lidocaine, 1 the effect on spinal PGE 2 release suggests caution, as the 'safety' margin we observed in PGE 2 release after single spinal levobupivacaine administration was narrower than expected. We suggest reducing the i.t. lidocaine dose and tailoring its use to the clinically requested block. Though a dose-dependent effect on PGE 2 release does not seem to apply after i.t. levobupivacaine administration, caution should still be exercised.
To summarize, we showed, using an in vivo analysis system, that i.t. injections of levobupivacaine transiently raised both PGE 2 and glutamate levels in the CSF. In contrast to levobupivacaine, higher PGE 2 responses after a second injection of 1000 mg lidocaine may suggest an increased level of local anaesthetic toxicity on the spinal cord with lidocaine.
